NEWS & EVENTS
FOR IMMEDIATE RELEASE
July 23, 2009
Contact: Gregg DiPietro
Leerink Swann
(617) 918-4601
Gregg.DiPietro@leerink.com
Contact: Risa Goldman Burgess/Laura Coluci
Schwartz Communications
(781) 684-0770
Leerink@schwartz-pr.com
LEERINK SWANN ADVANCES INVESTMENT BANKING FRANCHISE WITH KEY NEW HIRES
Healthcare Focused Investment Bank Adds Experienced Team of Investment Bankers from Bank of America Merrill Lynch
Boston, MA – July 23, 2009 – Leerink Swann, the leading healthcare investment bank, has recently recruited a team of investment bankers, including James Boylan, Bryan Giraudo, Tony Gibney and Mark Page. They will join the Firm upon completion of notice obligations to Bank of America Merrill Lynch. Jim Boylan will provide leadership as the new Head of Investment Banking and will continue to serve his clients across the pharma/biotech, medical device and healthcare services sectors. Messrs. Gibney, Giraudo and Page are joining the Firm as Managing Directors and together bring extensive relationships and transaction experience with life sciences and medical device companies.
In addition to these senior bankers, Eric Tansky, Brad Wolff and a team of highly talented mid and junior level bankers from Bank of America Merrill Lynch will be joining the Firm in August. With these additions, Leerink Swann has assembled an experienced senior origination contingent and a complete healthcare investment banking team of approximately 35 professionals.
“With the addition of this group and other recent hires including Jed Cohen and Adam Berger from Citigroup, Marc Grasso and Bill Reiland from Morgan Stanley, and Dan Lepanto from Cowen and Company, our senior investment banking team is well positioned to meet the needs of our clients across the entire strategic and product continuums,” said Jeffrey A. Leerink, Chairman and CEO of Leerink Swann. “This is consistent with our commitment to being the most knowledgeable healthcare investment bank. We will continue to differentiate based on healthcare knowledge and unbiased advice, and now boast unmatched transaction experience with this very formidable group of healthcare dedicated investment bankers.”
“The dislocation in the financial markets and the continued focus on proprietary capital transactions of the large universal banks have facilitated the resurgence of independent investment banking firms,” said James P. Boylan. “Our clients are increasingly focused on comprehensive solutions and are seeking knowledge-based and unbiased strategic advice. Leerink Swann has built an outstanding platform that is well positioned to partner with our clients to help them achieve strategic and financing objectives. The combination of a leading healthcare equity business, the unique insights of MEDACorp and Leerink Swann Strategic Advisors, creates a comprehensive strategic partnership for our clients that is unmatched in the business. We look forward to leveraging the power of this platform with our new colleagues to serve our clients.”
About James Boylan
James (Jim) Boylan, new Head of Investment Banking at Leerink Swann, brings 20 years of experience to the Firm. Jim built his investment banking career at Merrill Lynch over the past 12 years both as an M&A specialist and a healthcare origination banker with a focus on life sciences, medical device and healthcare services companies. His deal resume includes more than 80 completed transactions where he helped clients complete the full spectrum of M&A and financing transactions. Recent notable transactions include advising Celgene on its acquisition of Pharmion and advising Lifecell on its sale to Kinetic Concepts. Jim earned his M.B.A. from Columbia University and a B.S. from Lehigh University.
About Tony Gibney
Tony Gibney is a former Managing Director at Merrill Lynch in New York, where he led the Firm’s East Coast biotechnology and branded specialty pharmaceutical effort. Tony joined Merrill Lynch in 1999. Tony has executed over 75 lead advised M&A transactions and book-run financings, including IPO’s, follow-on offerings and convertible offerings, as well as sell-side, buy-side and corporate collaboration strategic advisory assignments for life science clients over his 16-year career in investment banking and in industry. Recent notable transactions include advising Virochem Pharma on its sale to Vertex Pharmaceuticals and advising Axcan Pharma on its sale to Texas Pacific Group. Tony earned a B.A. from Yale University.
About Bryan Giraudo
Bryan Giraudo joins Leerink Swann from Merrill Lynch in San Francisco, where he was responsible for the Firm’s West Coast mid and small cap biotechnology and medical technology relationships. Bryan joined Merrill Lynch in 1997. Bryan has executed more than 50 initial public offerings, follow-on and convertible financing transactions, as well as product and company buy-side, sell-side and corporate collaboration strategic advisory assignments for biotechnology, specialty pharmaceutical and medical technology clients over his 11-year career in investment banking. Recent transactions include Ventana Medical System’s hostile defense and subsequent sale to Roche and the sale of Cougar Biotechnology to Johnson & Johnson. Bryan received his B.A. from Georgetown University.
About Mark Page
Mark Page, a Managing Director at Leerink Swann, brings 13 years of experience to the Firm. Prior to joining Leerink Swann, Mark was a third-year Director in the Healthcare Investment Banking Group at Merrill Lynch in New York; Mark joined Merrill Lynch in 2001. Over the course of his career, Mark has completed over 60 strategic and financing transactions. Mark is focused on the medical device sector where his recent transaction experience includes advising Getinge AB on its acquisition of Datascope, Insulet and TomoTherapy's Initial Public Offerings and follow on equity offerings and acquisition-related financings for Inverness Medical. Mark earned his M.B.A. from The Wharton School at the University of Pennsylvania and his B.A. from Haverford College.
About Leerink Swann
Leerink Swann is a healthcare-focused investment banking firm that provides capital markets, mergers and acquisition, corporate finance, equity research, asset management and strategic advisory services. Since 1995, Leerink Swann has served as a trusted advisor to corporate, institutional and high-net-worth retail clients. Every year since 2001, Institutional Investor has named Leerink Swann “Best of the Boutiques” in several healthcare categories. Leerink Swann’s proprietary MEDACorp network, comprised of over 30,000 physicians, researchers and healthcare professionals provides unparalleled insights into cutting-edge advances in healthcare. Through its Strategic Advisory group, Leerink Swann provides consulting services to the leaders of healthcare companies and their financial sponsors on the strategic, financial and operational issues that most impact value, growth and profitability. With approximately 220 employees, Leerink Swann has offices in Boston, New York and San Francisco. Leerink Swann is a member of FINRA/SIPC. For more information, visit www.leerink.com.
- END -